Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

BACKGROUND: Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy. We wished to determine if the line...

Descripción completa

Detalles Bibliográficos
Autores principales: Migeotte, A., Dufour, V., van Maanen, A., Berliere, M., Canon, J. L., Taylor, D., Duhoux, F. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588736/
https://www.ncbi.nlm.nih.gov/pubmed/34763656
http://dx.doi.org/10.1186/s12885-021-08950-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588736/
https://www.ncbi.nlm.nih.gov/pubmed/34763656
http://dx.doi.org/10.1186/s12885-021-08950-x

Ejemplares similares